论文部分内容阅读
目的 :探讨原发性肝癌肝动脉灌注奥沙利铂致过敏反应的发生率、临床表现及其预防和处理对策。方法 :研究对象为2011年10月—2013年10月在复旦大学附属肿瘤医院接受奥沙利铂肝动脉灌注化疗的677例原发性肝癌患者,分析奥沙利铂过敏反应的发生率及其临床特征。结果 :677例患者中,18例(2.7%)发生奥沙利铂过敏,其中17例为轻~中度过敏反应,1例表现为重度过敏反应,给予常规吸氧、抗组织胺药物和类固醇激素治疗后,均可缓解。接受>3次奥沙利铂肝动脉灌注化疗的263例患者中,发生过敏的患者有16例(6.1%),过敏发生率显著高于接受1~3次的414例患者(0.5%),差异有统计学意义(P<0.001)。结论 :肝动脉灌注奥沙利铂治疗原发性肝癌较为安全,但肝动脉灌注化疗次数>3次者易引起过敏反应,应引起重视。
Objective: To investigate the incidence, clinical manifestation, prevention and treatment of allergic reaction induced by oxaliplatin in hepatic artery of primary liver cancer. Methods: The study was performed on 677 patients with primary liver cancer who underwent hepatic arterial infusion chemotherapy with oxaliplatin at the Affiliated Tumor Hospital of Fudan University from October 2011 to October 2013. The incidence of oxaliplatin allergy and its Clinical features. RESULTS: Of the 677 patients, 18 (2.7%) developed oxaliplatin allergy, of which 17 were mild to moderate anaphylaxis and 1 was severe allergic reaction. Conventional oxygen inhalation, antihistamine and steroid Hormone therapy, can be alleviated. Of the 263 patients who received> 3 oxaliplatin-IV hepatic arterial chemotherapies, 16 (6.1%) had anaphylaxis and 414 had a higher rate of allergy than 414 (0.5%) patients who received 1-3 cycles of hypersensitivity, The difference was statistically significant (P <0.001). Conclusion: Hepatic arterial infusion of oxaliplatin is more safe in the treatment of primary liver cancer, but it is easy to cause anaphylactic reaction when hepatic arterial infusion of chemotherapy> 3 times.